FDAsafety guidance66% confidence
Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Eugia Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Bone Metastases
- Sub-indication
- General
Related signal: Eugia Pharma submits supplemental application for Zoledronic Acid (ANDA209125)